Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Internal and Emergency Medicine|August 29, 2012
Patient preferences and willingness to pay for different options of anticoagulant therapyMarco Moia, Lorenzo Giovanni Mantovani, Monica Carpenedo, et al.
Mediterranean Journal of Hematology and Infectious Diseases|May 19, 2021
Practical Recommendations for the Management of Patients with ITP During the COVID-19 PandemicFrancesco Rodeghiero, Silvia Cantoni, Giuseppe Carli, et al.
Thrombosis Research|October 4, 2011
Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1)Sergio Siragusa, Ugo Armani, Monica Carpenedo, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 13, 2023
Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in ItalyMariasanta Napolitano, Nicola Vianelli, Lisanna Ghiotto, et al.
Platelets|December 6, 2024
Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experienceMonica Carpenedo, Arianna Zappaterra, Lorenzo Del Castello, et al.
Haematologica|July 21, 2022
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panelValerio De Stefano, Alessandra Larocca, Monica Carpenedo, et al.
European Journal of Haematology|December 17, 2016
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term responseMiriam Marangon, Nicola Vianelli, Francesca Palandri, et al.
Lancet (London, England)|October 1, 2023
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trialCatherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, et al.
Therapeutic Advances in Hematology|October 14, 2021
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendationsMonica Carpenedo, Erminia Baldacci, Claudia Baratè, et al.
American Journal of Hematology|May 1, 2020
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional studyFrancesca Schieppati, Laura Russo, Marina Marchetti, et al.
Pageof 4